Cellectis S.A. is a clinical-stage biotechnological company headquartered in Paris, France, focused on developing immuno-oncology products utilizing gene-edited T-cells that express chimeric antigen receptors to target cancer cells. The company's primary portfolio includes several allogeneic T-cell product candidates such as UCART19, designed for treating CD19-expressing hematologic malignancies, and UCART123 for acute myeloid leukemia. Additional candidates include ALLO-501 for relapsed/refractory diffuse large B-cell lymphoma, UCART22 for B-cell acute lymphoblastic leukemia, and products targeting multiple myeloma, such as UCARTCS1 and ALLO-715. In addition to its therapeutic developments, Cellectis also produces high oleic soybean oil and other agricultural products. The company has established strategic partnerships with various institutions, including Allogene Therapeutics and The University of Texas M.D. Anderson Cancer Center. Founded in 1999, Cellectis continues to innovate in the field of gene editing and immunotherapy.
Cellartis AB is a Swedish/British biotechnology company focused on pluripotent stem cells and technology for drug discovery research, toxicity testing and regenerative medicine Since 2001, Cellartis has worked globally with industry and academia, platform providers and end users to develop the next generation of advanced stem cell products and technologies. The company leverages a deep experience in stem cell handling, scale up and differentiation into mature and functional human cells. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools today.
Cyto Pulse Sciences
Acquisition in 2010
Cyto Pulse Sciences is a biomedical device and treatment development company. It develops electric field based devices for production of DNA therapeutic vaccines, delivery of DNA vaccines, modification of cell genomes to correct genetic defects, production of hybridoma cell vaccines by fusing immune system cells and tumor cells, and the production of hybridomas used to produce monoclonal antibodies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.